Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study

Antonia Valenzuela, Murray Baron, Canadian Scleroderma Research Group, Ariane L Herrick, Susanna Proudman, Wendy Stevens, Australian Scleroderma Interest Group, Tatiana S Rodriguez-Reyna, Alessandra Vacca, Thomas A Medsger Jr, Monique Hinchcliff, Vivien Hsu, Joy Y Wu, David Fiorentino, Lorinda Chung, Antonia Valenzuela, Murray Baron, Canadian Scleroderma Research Group, Ariane L Herrick, Susanna Proudman, Wendy Stevens, Australian Scleroderma Interest Group, Tatiana S Rodriguez-Reyna, Alessandra Vacca, Thomas A Medsger Jr, Monique Hinchcliff, Vivien Hsu, Joy Y Wu, David Fiorentino, Lorinda Chung

Abstract

Objectives: We sought to identify the clinical factors associated with calcinosis in an international multicenter collaborative effort with the Scleroderma Clinical Trials Consortium (SCTC).

Methods: This is a retrospective cohort study of 5218 patients with systemic sclerosis (SSc). Logistic regression was used to obtain odds ratios (OR) relating calcinosis to various clinical features in multivariate analyses.

Results: A total of 1290 patients (24.7%) had calcinosis. In univariate analyses, patients with calcinosis were older than patients without calcinosis, more likely to be female, and had longer disease duration from the first non-Raynaud phenomenon symptom. Patients with calcinosis were more likely to have digital ulcers, telangiectasias, acro-osteolysis, cardiac disease, pulmonary hypertension, gastrointestinal involvement, arthritis, and osteoporosis, but less likely to have muscle disease. Anti-Scl-70, RNA-polymerase-III, and U1-RNP autoantibodies were significantly less common in patients with calcinosis, while anticentromere (ACA), anti-PM/Scl, and anticardiolipin antibodies were more frequent. In multivariate analysis, the strongest associations with calcinosis were digital ulcers (OR = 3.9; 95% CI: 2.7-5.5; p < 0.0001) and osteoporosis (OR = 4.2; 95% CI: 2.3-7.9; p < 0.0001).

Conclusion: One quarter of patients with SSc have calcinosis at some time during their illness. Our data confirm a strong association of calcinosis with digital ulcers, and support a novel association with osteoporosis.

Keywords: Calcinosis; Digital ulcers; Osteoporosis; Systemic sclerosis.

Copyright © 2016 Elsevier Inc. All rights reserved.

References

    1. Gutierrez A, Jr, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012;25:195–206.
    1. Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin Rheumatol. 2015;27:542–8.
    1. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005;34:805–12.
    1. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol. 2012;148:455–62.
    1. Avouac J, Mogavero G, Guerini H, Drape JL, Mathieu A, Kahan A, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis. 2011;70:630–3.
    1. Koutaissoff S, Vanthuyne M, Smith V, De Langhe E, Depresseux G, Westhovens R, et al. Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. Semin Arthritis Rheum. 2011;40:455–60.
    1. Morardet L, Avouac J, Sammour M, Baron M, Kahan A, Feydy A, et al. Late nailfold videocapillaroscopy pattern associated with hand calcinosis and acro-osteolysis in systemic sclerosis. Arthritis Care Res. 2016;68:366–73.
    1. Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL. Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. Rheumatology (Oxford) 2012;51:2234–8.
    1. Steen VD, Ziegler GL, Rodnan GP, Medsger TA., Jr Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984;27:125–31.
    1. D’Aoust J, Hudson M, Tatibouet S, Wick J, Mahler M, Baron M, et al. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (Hoboken, NJ) 2014;66:1608–15.
    1. LeRoy EC, Medsger TA., Jr Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573–6.
    1. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA., Jr Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70:104–9.
    1. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013;65(11):2737–47.
    1. Morardet L, Avouac J, Sammour M, Baron M, Kahan A, Feydy A, et al. Late nailfold videocapillaroscopy patterns associated with hand calcinosis and acro-osteolysis in systemic sclerosis. Arthritis Care Res. 2016;68(3):366–73.
    1. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 2014;150:724–9.
    1. Valenzuela A, Chung L. Management of calcinosis associated with systemic sclerosis. Curr Treat Options Rheumatol. 2016;2:85–96.
    1. Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis-a risk factor for cardiovascular disease? Nature reviews Rheumatology. 2012;8:587–98.
    1. Fadini GP, Rattazzi M, Matsumoto T, Asahara T, Khosla S. Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation. 2012;125:2772–81.
    1. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vascular calcification and osteoporosis–from clinical observation towards molecular understanding. Osteoporos Int. 2007;18:251–9.
    1. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int. 2013;93:365–73.
    1. Omair MA, Pagnoux C, McDonald-Blumer H, Johnson SR. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(11):1881–90.
    1. Serup J, Hagdrup H, Tvedegaard E. Bone mineral content in systemic sclerosis measured by photonabsorptiometry. Acta Derm Venereol. 1983;63:235–7.
    1. da Silva HC, Szejnfeld VL, Assis LS, Sato EI. Study of bone density in systemic scleroderma. Rev Assoc Med Bras. 1997;43:40–6.
    1. Di Munno O, Mazzantini M, Massei P, Ferdeghini M, Pitaro N, Latorraca A, et al. Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis. Clin Rheumatol. 1995;14:407–12.
    1. Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, et al. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol. 2008;35:2206–13.
    1. Rabens SF, Bethune JE. Disodium etidronate therapy for dystrophic cutaneous calcification. Arch Dermatol. 1975;111:357–61.
    1. Fujii N, Hamano T, Isaka Y, Ito T, Imai E. Risedronate: a possible treatment for extraosseous calcification. Clin Calcium. 2005;15(Suppl.1):75–8. [discussion 8–9]
    1. Katayama I, Otoyama K, Kondo S, Nishioka K, Nishiyama S. Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol. 1990;23:198–201.
    1. Chung L, Valenzuela A, Fiorentino D, Stevens K, Li S, Harris J, et al. Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Arthritis Care Res. 2015;67:425–30.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren